Evaluation of the effect of Allopurinol in reducing heart damage in acute ischemic heart patients

Evaluation of Allopurinol effect on Plasma Level of Cardiac Troponin-I and Creatine Kinase- MB in acute ischemic heart disease (ACS)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20111206008307N36

Enrollment

100

Registered

2020-07-28

Start date

2019-11-22

Completion date

Unknown

Last updated

2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute cardiac ischemic patients. Non-ST elevation (NSTEMI) myocardial infarction

Interventions

Intervention 1: Intervention group: After diagnosis of ischemic heart disease, patients receive 600 mg of allopurinol, product of Hakim Pharmaceutical factory, in two divided doses on the first day an

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients diagnosed with acute ischemic heart syndrome Age 80-18 years Ability to understand and sign consent forms

Exclusion criteria

Exclusion criteria: Serum creatinine above 2 milligram Per deciliter Acute myocardial infraction History of dialysis Cardiogenic shock

Design outcomes

Primary

Measure	Time frame
Cardiac troponin I. Timepoint: Before, 8, 16, 24 and 32 hours after receiving allopurinol. Method of measurement: ELISA kits.;Creatine Kinase-MB. Timepoint: Before, 8, 16, 24 and 32 hours after receiving allopurinol. Method of measurement: ELISA kite.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Taher Entezari-maleki

Tabriz University of Medical Sciences

tentezari@gmail.com+98 41 1339 2593

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026